Alnylam Pharmaceuticals, Inc.

Total Valuation

Alnylam Pharmaceuticals, Inc. carries a market capitalization of 39.06B, placing it among publicly traded companies globally. Its enterprise value stands at 41.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Alnylam Pharmaceuticals, Inc. currently has 133.44M shares outstanding.

Valuation Ratios

Alnylam Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 75.55. The price-to-sales ratio is 10.17, and the price-to-book ratio stands at -6.71.

Enterprise Valuation

On an enterprise value basis, Alnylam Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 51.89 and an EV/FCF ratio of 39.31. The EV/Sales ratio of 9.77 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 55.67 provides insight into valuation relative to core operating earnings.

Financial Position

Alnylam Pharmaceuticals, Inc. maintains a current ratio of 3.13, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 118.38, indicating elevated leverage, while an interest coverage ratio of 2.85 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Alnylam Pharmaceuticals, Inc. has paid 9.18M in income taxes, reflecting an effective tax rate of 1.57.

Stock Price Statistics

Alnylam Pharmaceuticals, Inc.'s stock has declined approximately -3.68371% over the past 52 weeks. The 50-day moving average sits at 308.10, while the 200-day moving average is 384.17.

Income Statement

Over the trailing twelve months, Alnylam Pharmaceuticals, Inc. generated 4.29B in revenue and converted that into 577.22M in net income, yielding earnings per share of 4.26. EBITDA reached 806.94M, while operating income came in at 752.14M.

Balance Sheet

Alnylam Pharmaceuticals, Inc. holds 3.01B in cash and equivalents against 1.27B in total debt, resulting in a net debt position of -701.41M. Total book value stands at -6.50B, with working capital of 2.87B providing operational flexibility.

Cash Flow

Alnylam Pharmaceuticals, Inc. produced 714.90M in operating cash flow over the past twelve months. After subtracting -71.56M in capital expenditures, free cash flow totaled 643.34M - equivalent to 4.88 per share.

Margins

Alnylam Pharmaceuticals, Inc. operates with a gross margin of 80.83, reflecting its pricing power and cost economics. The operating margin of 17.54 and net profit margin of 13.46 provide insight into operational efficiency.

Dividends & Yields

Scores

Alnylam Pharmaceuticals, Inc. posts an Altman Z-Score of 6.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.